Our platform technologies are designed to administer cancer fighting tumor suppressor genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.
We are developing our lead product candidate, Oncoprex™ immunogene therapy, to be administered in combination with targeted therapies and immunotherapies for non-small cell lung cancer. Preclinical research indicates that Oncoprex might also be effective in fighting other types of cancer and we are exploring its use in other cancer types.
We are a multidisciplinary team with broad business experience in the biotech and pharmaceutical industries, and research and clinical experience at preeminent medical and academic institutions around the world. Our management team pairs an unmatched expertise with a knack for innovation in research.
At Genprex, we are committed to pioneering a new approach to treating cancer, based upon our novel proprietary technology platform, including our initial product candidate, Oncoprex™ immunogene therapy, or Oncoprex. Our platform technologies are designed to administer cancer fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.
Gene therapy is a big and trending topic in the world of medicine and has recently been making headlines as large pharmaceutical companies have been ramping up acquisitions of gene therapy companies. So how exactly does gene therapy work?
Genprex reported that its collaborators from The University of Texas MD Anderson Cancer Center presented positive preclinical data for the combination of the TUSC2 gene with an anti-PD1 antibody, pembrolizumab, for the treatment of lung cancer in a poster presented at the American Association of Cancer Research Meeting 2019.
Genprex today announced a clinical and corporate update and the filing of financial results for the year ended December 31, 2018 on Form 10-K with the United States Securities and Exchange Commission.
The gene therapy market is experiencing tremendous excitement, and these acquisitions strengthen the position that gene therapy is now a significant and key treatment option for patients with serious diseases or cancer.
We’re passionate about the work we’re doing to revolutionize the fight against cancer, and we want to keep our current and potential investors informed on our day-to-day advancements. For up-to-the-minute company news delivered straight to your inbox, sign up for our email newsletter.